Medical Progress Today
mpt home | sign up

Volume 3, Number 15
April 28, 2006


PRINTER FRIENDLY

In the Spotlight

Good News on Evista Comes Too Late for Some

Gilbert L. Ross, M.D., Medical Progress Today, 4-28-06

The National Cancer Institute–sponsored STAR (Study of Tamoxifen and Raloxifene) trial brings good news for women, especially those at a higher–than–average risk of breast cancer.[1] Lilly's estrogen modulator, raloxifene (Evista), prevented breast cancer just as efficiently as the only drug approved by the Food and Drug Administration (FDA) for this purpose, tamoxifen. Both drugs reduced the risk of invasive breast cancer in postmenopausal women by about half (though tamoxifen—which has been used to treat breast cancer for over twenty–five years and to prevent it since 1998—also lowered the risk of non–invasive ductal lesions, while raloxifene did not). Moreover, Evista was safer than tamoxifen, with fewer clots, cataracts, and instances of uterine cancer.
Continue reading . . .


Medical Progress Today is published by the Center for Medical Progress at the Manhattan Institute for Policy Research.

For more information about Medical Progress Today, please contact the managing editor, Paul Howard, at phoward@manhattan-institute.org, or via telephone at 212.599.7000.

Press inquiries regarding Medical Progress Today can be directed to the Communications Department, at communications@manhattan-institute.org, or via telephone at 212.599.7000.

If you would like to unsubscribe, please reply to us and type "Unsubscribe" in the subject line.

In this week's issue:

SPOTLIGHT

Good News on Evista Comes Too Late for Some
Center for Medical Progress 
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000
mpt@manhattan-institute.org